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Abstract
Background
Lynch syndrome is a hereditary cancer syndrome caused by constitutional pathogenic vari-
ants in the DNA mismatch repair (MMR) system, leading to increased risk of colorectal,
endometrial and other cancers. The study aimed to identify the incremental costs and con-
sequences of strategies to identify Lynch syndrome in women with endometrial cancer.
Methods
A decision-analytic model was developed to evaluate the relative cost-effectiveness of reflex
testing strategies for identifying Lynch syndrome in women with endometrial cancer taking
the NHS perspective and a lifetime horizon. Model input parameters were sourced from vari-
ous published sources. Consequences were measured using quality-adjusted life years
(QALYs). A cost-effectiveness threshold of £20 000/QALY was used.
Results
Reflex testing for Lynch syndrome using MMR immunohistochemistry and MLH1 methyla-
tion testing was cost-effective versus no testing, costing £14 200 per QALY gained.
There was uncertainty due to parameter imprecision, with an estimated 42% chance
this strategy is not cost-effective compared with no testing. Age had a significant impact on
cost-effectiveness, with testing not predicted to be cost-effective in patients aged 65 years
and over.
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Conclusions
Testing for Lynch syndrome in younger women with endometrial cancer using MMR immu-
nohistochemistry and MLH1 methylation testing may be cost-effective. Age cut-offs may be
controversial and adversely affect implementation.
Introduction
Lynch syndrome (LS) is a hereditary cancer syndrome caused by pathogenic variants (muta-
tions) in the mismatch repair (MMR) genes which leads to an increased risk of cancers, partic-
ularly colorectal cancer (CRC) and endometrial cancer (EC) [1]. Around 1 in 300 of the
general population is born with a pathogenic variant in an MMR gene (estimates include 1 in
370 [2] and 1 in 279 [3]), but these are overrepresented in cancer patients, and particularly
young cancer patients.
LS is typically identified through cancer-affected individuals and testing is typically driven
by tumour-based triage tests. The automatic application of these tests to eligible patients is
termed reflex testing. When a pathogenic variant is identified, predictive testing can be offered
to relatives, usually through cascade testing to minimise the number of wasted tests.
Interventions to reduce the risk of cancer incidence and mortality for families with LS
include surveillance, risk-reducing surgery, and aspirin chemoprevention [1].
Reflex testing for LS is cost-effective in CRC [4–6] and is recommended in England [7].
The clinical and economic value of reflex testing for LS in EC patients may differ from reflex
testing in CRC patients because: EC may be a common sentinel cancer with good survival
(patients have more potential to benefit from subsequent interventions); the distribution of
variants implicated in EC differs from CRC; the biomarker BRAF V600E, useful in CRC, has
no utility in EC.
We know of three economic evaluations of reflex testing for LS in women with EC, none in
the NHS setting, and none including a no testing comparator [8–10].
The aim of this study is to identify the relative cost-effectiveness of reflex testing for LS in
women with EC in the NHS.
Methods
This study used methods in line with the NICE reference case [11] to address the decision
problem specified in Table 1 and is reported in line with published criteria [12].
Relevant population
Reflex testing is conducted in women newly diagnosed with EC (probands), so the population
includes all women diagnosed with EC even if they do not have LS. Relatives may also subse-
quently be diagnosed with LS by predictive testing, so all relatives who could feasibly be diag-
nosed are modelled in the population, even if neither they nor the proband have LS or receive
testing (maintaining a consistent population across interventions).
The prevalence of LS among probands declines with age, as do the opportunities to inter-
vene meaningfully, therefore cost-effectiveness is sensitive to the age of probands. The model
simulates a cohort of probands of a specific age (60 years in the base case) so that the impact of
age on cost-effectiveness can be quantified.
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The age distribution of relatives also affects cost-effectiveness, since younger relatives have a
greater opportunity to benefit from interventions. In the base case analysis and scenario analyses
we use a weighted average of the results considering the full distribution of relatives’ ages, while in
the probabilistic and one-way sensitivity analyses relatives start the model aged 54 as this produces
cost-effectiveness results closest to a weighted average of results across relatives’ ages.
Selection of relevant interventions and comparators
Five reflex testing strategies were identified following consultation with clinical experts, plus a
no testing option (representing current practice). Four strategies utilised tumour tests to triage;
the fifth involved direct referral to genetic counselling for mutation testing. We did not include
the use of tools to predict the risk of LS [13] as interventions in our base case analysis as these
require taking good quality family history, which may not be feasible for some patients, incurs
costs, and may be challenging in clinical settings. We have included them in a scenario analy-
sis. It should be noted that in a fully incremental cost-effectiveness (as is conducted in this
study), any convex combination of strategies is implicitly included. For example, if the true
current practice was that 80% of hospitals did no testing and 20% of hospitals used a particular
reflex testing strategy, the explicit inclusion of this would make no difference to the cost-effec-
tiveness results (assuming the 20% sample was effectively random).
Model structure
We modelled the following care pathways:
• Diagnostic testing in women with EC to identify those with LS;
• Genetic testing of male and female relatives of those women with LS to identify further cases
of LS;
Table 1. Key design criteria for economic evaluation.
Decision problem What is the relative cost-effectiveness of strategies to identify LS in women with EC?
Intervention and
comparators
Reflex testing with MMR IHC (with or without MLH1 methylation testing if MLH1 stain
abnormal) followed by referral for LS diagnostic mutation testing
Reflex testing with MSI (with or without MLH1 methylation testing if MSI identified)
followed by referral for LS diagnostic mutation testing
Direct referral to genetic counselling for LS diagnostic mutation testing
No testing for LS
Model type Decision tree and Markov model implemented in Excel 2013 (Microsoft; Redmond,
WA)
Population Women newly diagnosed with EC (probands), and their relatives who may be reached
for predictive testing if a pathogenic mutation is identified
Setting Healthcare services, including costs to the NHS and personal social services but
excluding other governmental or societal costs
Time horizon Lifetime (until death or age 100 years)
Costs Pounds sterling (£; GBP) in 2016/17 prices
Benefits QALYs
Discounting 3.5% for costs and benefits
Cost-effectiveness
threshold
£20 000 per QALY
Key: EC, endometrial cancer; GBP, Great Britain pounds (sterling); IHC, immunohistochemistry; LS, Lynch
syndrome; MMR, mismatch repair; MSI, microsatellite instability; NHS, National Health Service; QALY, quality-
adjusted life year
https://doi.org/10.1371/journal.pone.0221419.t001
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• Biennial colonoscopic surveillance for CRC for those having, or suspected of having LS.
The model focussed on CRC outcomes for patients as this has a significantly greater burden
in terms of mortality for people with LS than other cancers. For comparison, in a prospective
study of LS, incidence and 5-year survival figures suggest 4.5 deaths from colorectal cancer for
every 1 death from ovarian cancer [14] (it should be noted that this was in the presence of colo-
noscopic surveillance, so more deaths may have been expected otherwise).
Three diagnostic categories were included: LS (pathogenic constitutional MMR variant
identified), putative LS (PLS; no pathogenic variant identified, but tumour-based tests and
family history suggestive of LS) and sporadic. Women diagnosed with (P)LS were offered
interventions to reduce the incidence and mortality of CRC. Relatives of women diagnosed
with LS were offered predictive mutation testing, with risk-reducing interventions offered to
those with the variant. First-degree relatives of women diagnosed as PLS were invited to
genetic counselling and offered biennial colonoscopic surveillance.
The model was a decision tree (Fig 1) where the long-term outcomes (costs and QALYs)
were estimated using a Markov model (Fig 2).
A Markov cycle length of one month was employed; transitions were assumed to occur
midway through each cycle [15].
Model parameters
The model inputs were populated from various sources:
• Clinical data were sourced from published literature through pragmatic literature review (S1
Appendix).
Fig 1. Conceptual decision tree for probands. Key: FH, family history; LS, Lynch syndrome; PLS, putative Lynch syndrome.
https://doi.org/10.1371/journal.pone.0221419.g001
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• Epidemiological data were sourced from published literature or national statistics.
• Cost data were sourced from published literature, NHS reference costs [16] and NHS price
lists for tests as offered to other NHS providers.
• Health-related quality of life was estimated from the published literature through pragmatic
literature review.
Model input parameters are described according to their function:
• Natural history–How LS is manifested in the model population in the absence of any
interventions;
• Diagnostic accuracy–How accurate diagnostic tests are at detecting Lynch syndrome;
• Preventive effectiveness–How effective risk-reducing measures are;
• Utility values–The preference weights attached to different health states;
• Costs–The relevant costs identified for interventions, events and outcomes.
Natural history. The prevalence of LS in EC was estimated based on results from sixteen
studies of testing for LS in endometrial cancer [13, 17–31] and from national statistics of six
countries [32–37]. The prevalence was estimated as 3.9% overall [13, 17–31], but dependent
on age and with heterogeneity between studies (S2 Appendix). When studies at risk of bias
due to high dropout (� 10%) were excluded, the estimated prevalence was reduced to 3.0%.
Lynch syndrome gene mutations in MLH1 and MSH2 are associated with earlier age of
onset of endometrial cancer than mutations in MSH6 and PMS2 and non-Lynch syndrome
Fig 2. Simplified model diagram for long-term outcomes. Key: CRC, colorectal cancer. Future EC incidence was not
included because all probands have already had EC and the vast majority have had a hysterectomy. Female relatives
with LS are at risk of EC, but as a simplifying assumption this was not included.
https://doi.org/10.1371/journal.pone.0221419.g002
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endometrial cancer. These mutations may also not be evenly distributed in the population. To
estimate the distribution of gene mutations for probands of a given age, we estimated the over-
all relative abundance of the genes in endometrial cancer patients (of any age) by pooling stud-
ies reporting gene distributions and imposing an age limit for testing of 70 years or higher or
no limit. Sixty-five endometrial cancer patients with identified MMR mutations across eight
studies [18, 20–24, 28, 31] contributed to these estimates of 16.9%—24.6%—47.7%—10.8% for
MLH1—MSH2—MSH6—PMS2. The age-specific relative abundance was then estimated by
considering the age-dependent risks of endometrial cancer reported from the Prospective
Lynch Syndrome Database (PLSD) [14]. A restricted cubic spline model with three knots was
used, and the resulting gene distributions predicted at 5-year intervals are given in Table 2.
Probands enter the model with EC and the associated mortality risk. Survival of EC is better
for women with LS compared to those with sporadic EC. The mortality rate for women with LS
was estimated as 4.0 per 1000 person years based on an analysis from prospectively registered
women with LS [14]. The mortality rate for sporadic EC was estimated from national statistics
on 5-year survival according to age and ranged from 26.4 to 92.1 per 1000 person years [38].
To estimate the incidence of CRC in individuals with LS, survival models were fitted to
reported data from the Prospective Lynch Syndrome Database (PLSD) [14, 39, 40]. Individuals
with MLH1 mutations were predicted to have the highest risk, with MSH2, MSH6 and PMS2
mutation carriers having progressively lower risks (S3 Appendix).
These estimates were used for individuals with LS undergoing surveillance; CRC incidence
for individuals with LS not receiving surveillance was estimated by applying the (inverted) haz-
ard ratio for incidence due to surveillance colonoscopy (see below) to these estimates.
CRC incidence for individuals without LS was estimated from national statistics [35].
CRC mortality for individuals without LS was estimated from national 5-year survival sta-
tistics [41].
CRC survival is improved for individuals with LS, except for metastatic disease. The CRC
mortality rate for individuals with LS was estimated by applying a hazard ratio of 0.66 for
Stage I–III CRC [42].
Diagnostic accuracy. For each tumour-based test, the sensitivity, specificity and test fail-
ure rate were estimated.
Meta-analyses of sensitivity and specificity were performed using the bivariate method [43]
without covariates (see S4 Appendix for details of methods and results).
Eight studies [13, 17, 19, 21, 22, 24, 25, 30] were identified providing estimates of the diag-
nostic performance of IHC. The sensitivity and specificity of IHC were estimated as 94.4% and
74.8%. The test failure rate was estimated from eight studies [17, 19, 21, 22, 24, 25, 28, 31]
across which 16 test failures were reported from 1037 patients, with a mean estimate of 3.7%.
The proportion of positive IHC results with absent/abnormal staining of MLH1 was
assumed to be 89% in those with an MLH1 mutation [13, 19–22, 25, 26, 30, 31, 44], 0.6% in
Table 2. MMR gene mutation distribution in endometrial cancer patients.
Age (years) MLH1 (%) MSH2 (%) MSH6 (%) PMS2 (%)
50 17.0 28.6 47.1 7.3
55 13.6 28.4 49.8 8.2
60 11.0 28.5 51.4 9.0
65 8.8 29.2 52.3 9.7
70 6.9 30.5 52.6 10.0
75 5.2 32.1 52.4 10.2
80 3.9 33.9 51.9 10.3
https://doi.org/10.1371/journal.pone.0221419.t002
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individuals with non-MLH1 mutations [13, 17, 19–22, 24–26, 28, 30, 31, 44], and 83% in indi-
viduals without LS [13, 17, 19–22, 24–26, 28, 30, 31, 44].
Eight studies [13, 17, 19, 21, 22, 24, 25, 30] were identified which provided estimates of the
diagnostic performance of MSI. Half of these [13, 17, 25, 30] categorised tumours as MSI if
�1/5 markers showed instability, while the rest [19, 21, 22, 24] categorised tumours as MSI if
�2/5 markers showed instability. No threshold effect was observed, so studies were pooled
without a covariate in the meta-analysis. One study [30] showed very poor sensitivity and con-
tributed to numerical issues in the meta-analysis, and was excluded on this basis.
The sensitivity and specificity of MSI were estimated as 90.3% and 77.1%. The test failure
rate was estimated from six studies [13, 19, 21, 22, 24, 25] across which 12 failures were reported
from 1195 patients, with failure rates ranging from 0% to 5%, and a mean estimate of 1.9%.
Seven studies [17, 20, 21, 24, 25, 28, 31] estimated the performance of MLH1 methylation
testing following abnormal IHC results for MLH1. As no studies discovered methylated tumours
with germline mutations, it is not possible to estimate the sensitivity through meta-analysis. A
number of studies did not test for germline mutations if MLH1 methylation was identified in the
tumour, but two did [20, 25], and in another study [21] blood DNA was also tested to identify
constitutional methylation. Sensitivity was assumed to be 95%, i.e., 95% of those with constitu-
tional MLH1 mutations do not show methylation. Specificity was estimated as 93.6%, applying
to those without MMR mutations and those with MSH2, MSH6 and PMS2 mutations.
Only one study estimated the performance of MLH1 methylation testing following detec-
tion of MSI [23], since all other studies conducting MSI and MLH1 methylation testing also
performed IHC and only performed MLH1 methylation testing if MLH1 staining was absent/
abnormal. Therefore, we assumed for patients with an MLH1 mutation the sensitivity would
be equivalent in patients with MSI as those with dMLH1 (95%). For patients with mutations in
MSH2, MSH6 and PMS2, we estimated that 1/14 would demonstrate MLH1 methylation and
be inappropriately discharged from further testing [20]. For patients without a constitutional
MMR mutation, we assumed 67% would demonstrate MLH1 methylation and be discharged
from further testing [20]. In a scenario analyses we use estimates from Hampel et al. [23] for
these parameters.
Mutations causing LS are numerous and heterogeneous. Furthermore, heritable mutations
can have epigenetic effects on the MMR genes (e.g., constitutional MLH1 methylation). Most
of these LS-causing mutations are readily detected, although some may be more challenging to
identify. Interpretation is coordinated internationally [45].
It was assumed diagnostic mutation testing only identifies and classifies mutations truly
causing LS as pathogenic (i.e., 100% specificity). It is further assumed the sensitivity of diag-
nostic mutation testing is 90%, i.e., 10% of LS-causing mutations are not identified.
It was assumed predictive mutation testing is 100% accurate.
It was assumed 55% of EC patients with tumour-based test results suggestive of LS would
attend genetic counselling [46], and 10% of these would decline diagnostic mutation testing [47].
Preventive effectiveness. The effectiveness of colonoscopic surveillance is a key determi-
nant of the cost-effectiveness of strategies to identify LS [4, 5].
Ladabaum et al. [48] reviewed the literature and found five observational studies [49–53]
estimating the impact of surveillance on CRC incidence, stage on diagnosis and mortality.
Estimates from a study by Ja¨rvinen et al. [51] have been used in a number of economic eval-
uations [4, 5, 47, 54]. The use of this study was considered carefully [4] in light of the higher
than expected incidence of CRC in the PLSD [14], as well as the absence of evidence that more
frequent colonoscopy in MLH1 cases is more effective [55]. Of the studies identified by Lada-
baum et al. [48], the study by Ja¨rvinen et al. estimates the second smallest impact on CRC inci-
dence, with only Arrigoni et al. [49] estimating a smaller impact.
Cost-effectiveness of testing for Lynch syndrome in women with endometrial cancer
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Estimates for the impact of colonoscopic surveillance on CRC incidence were therefore esti-
mated from Ja¨rvinen et al. [5, 51] in the base case, probabilistic sensitivity analysis and one-
way sensitivity analyses; and from Arrigoni et al. [49] in a scenario analysis.
CRCs were assumed to be detected in earlier stages in those undergoing surveillance [56].
Utility values. Consistent with the NICE reference case [11], we sought to only include
direct health effects on patients. We therefore excluded non-health effects (such as information
and empowerment) for which people may be prepared to forgo other consumption, and spill-
over effects on family members not involved in the modelled care pathways [57, 58].
Baseline utility values (according to age and sex) were estimated from population norms
[59], with impacts on health-related quality of life acting multiplicatively on baseline utility
[60].
There is little evidence that non-metastatic CRC is associated with a lower (health-related)
utility than population norms [5]. Therefore, it was assumed there was no disutility associated
with Stage I-III CRC. Metastatic CRC is associated with significantly worse utility compared to
non-metastatic CRC [61], so we scaled utility by 0.79 for Stage IV CRC.
Although health-related quality of life may be significantly worsened in a small minority of
EC patients, it was assumed that on average there would be no disutility from population
norms.
Genetic testing can have a number of different effects on what would broadly be considered
utility, although its impact on health-related quality of life is more commonly investigated in
terms of the impact on anxiety, depression and mood [57, 62].
A pragmatic search of Embase and MEDLINE using a search filter for utility values [63]
failed to identify any studies measuring health-related quality of life in patients undergoing
testing for LS using generic preference-based measures.
In the base case analysis, it was assumed that there would be no direct impact on QALYs
from genetic counselling or genetic testing.
Costs. Costs are presented in 2016/17 pounds Sterling (£; GBP), inflated using the Hospi-
tal and Community Health Services Pay and Prices Index [64] to 2015/16 and then by 1.1% to
2016/17.
IHC, MSI and methylation were estimated to cost £210, £202 and £136 [4] as averages of
costs reported by genetics laboratories and personal communications.
The cost of offering counselling to a proband was estimated as £27 (15 minutes of Band 6
hospital nurse time). The cost of referral for a relative was estimated as £36 (cost of a general
practitioner appointment) [64].
Pre-test genetic counselling was estimated to cost £347 and £172 for probands and relatives
respectively, and post-test genetic counselling was estimated to cost £133 [65].
The cost of diagnostic mutation testing for LS was estimated as £755 (the midpoint of prices
offered by two genetics laboratories offering testing in all four genes for NHS patients). The
cost of predictive mutation testing was estimated as £166 (the average of all costs for predictive
testing in a single MMR gene [66]).
The cost of colonoscopy was estimated from NHS reference costs [16], including diagnostic
and therapeutic colonoscopies (£583). Biennial colonoscopy is recommended, but it is antici-
pated that due to pressures on colonoscopy services and due to missed appointments, the aver-
age interval would be approximately 2.1 years.
A one-off cost of CRC is incurred at the time of CRC incidence (dependent on the patient
age and stage at diagnosis), with no further cost being accrued due to time in CRC states or at
time of death from CRC.
The source of cost estimates is a report by the Economic Evaluation of Health and Social
Care Interventions Policy Research Unit [67], based on a whole-disease model of CRC [68].
Cost-effectiveness of testing for Lynch syndrome in women with endometrial cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0221419 August 30, 2019 8 / 18
Lifetime costs were estimated with future costs discounted at 3.5% and were assumed to be in
2010/11 prices.
Summary. S5 Appendix provides a full listing of model input parameters.
Analysis
Fully incremental analyses are performed throughout.
A base case deterministic analysis was conducted, holding all model input parameter values
fixed at a central estimate. A probabilistic sensitivity analysis (PSA) was conducted, in which
parameter values were simultaneously varied according to distributions reflecting their uncer-
tainty [69]. One-way sensitivity analyses were conducted, in which one parameter was varied
across a range while other model input parameter values were fixed at their base case value.
Calculations were made using the cohort method. Scenario analyses were performed to iden-
tify the importance of certain parameter and structural assumptions.
Results
Base case
All testing strategies were predicted to result in net QALY gains and increased costs versus no
testing.
MSI with methylation was predicted to result in the least QALY gains of the testing strate-
gies, due to diagnosing the lowest number of people with LS or as PLS. IHC-based strategies
were predicted to result in greater QALY gains than equivalent MSI-based strategies as they
were more sensitive. Methylation-based strategies were predicted to result in lower QALY
gains than equivalent strategies without methylation testing as they are less sensitive.
IHC with methylation was the testing strategy predicted to have the lowest total cost. IHC
without methylation was predicted to have the highest total cost. The use of methylation test-
ing substantially reduced costs.
Only IHC with methylation would be considered cost-effective at a threshold of £20 000
per QALY (Table 3).
Table 3. Cost-effectiveness results.
Strategy Incremental QALYs vs. no testing Incremental costs vs. no testing (£) ICER vs. no testing (£/QALY) Fully incremental ICER (£/QALY)
Base case
MSI with methylation 34.5 545 000 15 800 Dominated
Direct mutation
testing
35.1 769 000 21 900 Dominated
IHC with methylation 37.9 538 000 14 200 14 200
MSI 38.3 771 000 20 100 Extendedly dominated
IHC 40.2 826 000 20 600 129 000
Probabilistic sensitivity analysis
MSI with methylation 37.6 573 000 15 200 Dominated
Direct mutation
testing
38.0 767 000 20 200 Dominated
IHC with methylation 41.4 554 000 13 400 13 400
MSI 42.7 855 000 20 100 Extendedly Dominated
IHC 45.1 923 000 20 500 98 800
Key: ICER, incremental cost-effectiveness ratio; IHC, immunohistochemistry; MSI, microsatellite instability (testing); QALY, quality-adjusted life year.
Notes: Based on a population of 1000 probands and 6000 relatives (average in probabilistic sensitivity analysis); Results given to 3 significant figures.
https://doi.org/10.1371/journal.pone.0221419.t003
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Exploration of heterogeneity
The age of probands was varied from 40 to 85 years (not changing the distribution of the ages
of relatives). The economic values of all testing strategies strictly decreased with increasing
proband age. Across this range, IHC with methylation produced the most net health benefit of
the testing strategies (at a willingness to pay of £20 000 per QALY), although the incremental
net health benefit of this strategy (versus no testing) became negative for probands aged 65
years and upwards.
To examine the policy impact of heterogeneity, we estimated the cost-effectiveness of test-
ing with IHC and methylation versus no testing when the population is individuals aged up to
a particular age threshold. This analysis suggests that maximum economic value is achieved
when the age threshold is somewhere between 60 and 65 years, but that using an age threshold
of 70 years would produce more economic value than a threshold of 50 years, and that even
with an age threshold of 80 years there is still positive economic value versus no testing. This
happens because testing in younger endometrial cancer patients subsidises the testing in older
patients.
Exploration of uncertainty
Probabilistic sensitivity analysis. A probabilistic sensitivity analysis (PSA) was con-
ducted with 1000 iterations. The mean results were consistent with the base case analysis, in
that only IHC with methylation was predicted to be cost-effective at a threshold of £20 000 per
QALY (Table 2). There is decision uncertainty due to parameter imprecision, since IHC with
methylation is only the optimal strategy in 36% of iterations at a threshold of £20 000 per
QALY (Fig 3). The 95% credible interval for the incremental net monetary benefit of IHC with
methylation versus no testing is −£436 to £2204 per proband, and it was negative in 42% of
iterations.
Another PSA was conducted with the age of probands set to 50 (instead of the base case 60
years). IHC with methylation was predicted to be the optimal strategy in 45% of iterations, and
to be cost-effective compared to no testing in 90% of iterations.
One-way sensitivity analyses. One-way sensitivity analyses were conducted with lower
and upper parameter values equal to the 95% confidence limits for each parameter in the prob-
abilistic sensitivity analysis (Fig 4). The most influential parameters are the age of the proband
and the effectiveness of colonoscopy in reducing CRC incidence. Six parameters had the
potential to make testing not cost-effective within the ranges considered.
Scenario analyses. A number of scenario analyses were conducted to examine key param-
eter and structural assumptions. In all but one of these scenario analyses, IHC with MLH1
methylation testing remained cost-effective. In the scenario where the effectiveness of colono-
scopic surveillance at reducing CRC incidence was estimated from Arrigoni et al. 2005 [49],
none of the testing strategies was cost-effective (S6 Appendix). When risk prediction tools
were included as testing options, these were all less effective (produced fewer QALYs) than the
existing testing strategies, and they were all dominated or extendedly dominated and so would
not be considered cost-effective.
Discussion
This economic evaluation found that testing for LS in EC patients may be cost-effective in
women aged 60 using MMR immunohistochemistry and MLH1 methylation testing. Stronger
conclusions cannot be drawn from the current analysis as there remains a substantial possibil-
ity that testing (especially at ages close to 60) is less cost-effective than no testing. At a lower
age limit (50 years), there can be reasonable confidence that testing with IHC (or MSI) with
Cost-effectiveness of testing for Lynch syndrome in women with endometrial cancer
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methylation testing is cost-effective compared to no testing. Of interest, however, is the finding
that the optimal programme (from a cost-effectiveness perspective) would test all endometrial
cancer patients up to an age threshold somewhere between 60 and 65. Furthermore, pro-
grammes testing all endometrial cancer patients up to age 70 or 80 years would also be cost-
effective compared to no testing, even though they would not be cost-effective compared to a
programme using an optimised age threshold.
Three studies have previously addressed the cost-effectiveness of testing for LS in EC.
Goverde et al. [8] conducted an economic evaluation alongside a trial testing for LS in 179 EC
patients, extrapolating effectiveness based on previous economic evaluations. They found that
testing EC<70 years with IHC and MLH1 methylation testing would be cost-effective com-
pared to testing EC<50 years or using the revised Bethesda guidelines. Kwon et al. [9] used a
Markov model to estimate the cost-effectiveness of testing for LS in EC patients and found that
using family history and IHC would be cost-effective versus using age criteria, reflex IHC or
family history criteria alone. Resnick et al. [10] used a decision tree to answer a similar ques-
tion, and found that using IHC could be cost-effective versus using Amsterdam criteria,
depending on the value of detecting an LS case.
Our study adds significantly to the literature: it provides an estimate of cost-effectiveness in
the UK setting, it includes a no testing option (important given that current practice in most
Fig 3. Cost-effectiveness acceptability curve from probabilistic sensitivity analysis. Key: IHC, immunohistochemistry; MSI, microsatellite instability (testing);
QALY, quality-adjusted life year.
https://doi.org/10.1371/journal.pone.0221419.g003
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settings is no testing) and measures health effects in QALYs, as opposed to life years gained or
cases detected.
Our study has limitations; only CRC has been included as a downstream cancer, and we
have not included risk-reducing measures besides colonoscopy. Aspirin is cheap and effective
at lowering the risk of LS-associated cancers [70] and prophylactic gynaecological surgery vir-
tually eliminates the risk of EC and ovarian cancer [71]. On the other hand, gynaecological
surveillance is often recommended in spite of no convincing evidence for effectiveness or cost-
effectiveness. Estimates for key parameters have also been derived through pragmatic literature
review, so a systematic review, particularly one which focused on the comparative accuracy of
IHC and MSI, could be valuable. Our model assumes the proportion of EC with abnormal
IHC which specifically show MLH1 abnormalities, is independent of age, although some evi-
dence suggests an association [20].
Our study also assumes that there is no testing for MMR deficiency in endometrial cancer
in the no testing comparator. It may be that this testing is already being done, or will be done
in the near future, to select patients for targeted immune therapies [72]. In this instance we
would expect the cost-effectiveness of tumour testing-based strategies to be significantly
improved for those patients as there would be zero incremental costs for those tests.
IHC is conducted to a high standard in the UK, with use of external quality assurance. It is
likely that published studies based in research centres will have similarly high standards, but
routine clinical settings outside the UK may have lower standards. We have also assumed
(based on the literature) that IHC would use all four MMR proteins implicated in LS, although
it may be argued that testing for MSH6 and PMS2 expression could be cheaper and equally
effective. If a 2-protein IHC panel were equally effective and 35% cheaper than a 4-protein
panel, the ICER would reduce to £12,100 per QALY compared to no testing.
We have not included any genetic testing for somatic MMR mutations, which is sometimes
used (typically in research settings) to confirm that a MMR deficient tumour with no constitu-
tional pathogenic variant identified has arisen due to somatic MMR mutations rather than
from Lynch syndrome. This would be expected to increase costs. An alternative strategy for
testing could include testing for pathogenic MMR variants in tumour and normal colon tissue
and only referring to clinical genetics when the results suggest a constitutional pathogenic vari-
ant (which would then be confirmed by further testing). If this testing could be performed for
substantially less than the cost of genetic counselling it could be cost-effective, but current esti-
mates do not support this being the case.
There is a need for high-quality estimates of the effectiveness of surveillance colonoscopies.
Although the use of randomised controlled trials is unsuitable, this does not preclude other
study designs. As colonoscopies have cost implications for health services, often lead to dis-
comfort and occasionally serious complications for those receiving them, it is important their
true value in this setting is ascertained. We recommend research into the uptake of genetic
counselling and testing in the UK in the context of reflex tumour-based testing. The current
study assumes nearly half of patients decline genetic counselling, but this is based on a study in
an insurance-based healthcare system, and could lead to an underestimate of the cost-effective-
ness of testing. As shown in the one-way sensitivity analysis, if only 9% decline counselling fol-
lowing tumour testing, the incremental net benefit of testing is more than doubled (the ICER
drops to £11,500 per QALY).
Fig 4. Tornado diagram of one-way sensitivity analysis. Key: IHC, immunohistochemistry; INMB, incremental net monetary benefit (presented per
proband); QALY, quality-adjusted life years; WTP, willingness-to-pay; S5 Appendix gives details of all parameter abbreviations. Notes: Only includes
parameters with INMB range� 1% of maximum INMB range.
https://doi.org/10.1371/journal.pone.0221419.g004
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Conclusions
We recommend that concerns of cost-effectiveness should not be a barrier to implementing
reflex testing for LS in young women with EC. We recommend that the use of an age limit is
justified as older women (and their relatives) have less potential to benefit from testing, as the
likelihood of a positive test result is lower. Where the use of age limit is unacceptable, further
research should be conducted into the cost-effectiveness of testing before it is performed in all
EC patients.
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